Recombinant human interleukin‐1 receptor type I in the treatment of patients with active rheumatoid arthritis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective. To determine the safety and efficacy of recombinant soluble human interleukin‐1 receptor type I (rHuIL‐1RI) administered subcutaneously in patients with active rheumatoid arthritis (RA). Methods. Twenty‐three patients with active RA (>5 swollen joints) were enrolled into a randomized, double‐blind, 2‐center study. Patients received subcutaneous doses of rHuIL‐1RI or placebo for 28 consecutive days. Patients were treated with 125, 250, 500, or 1,000 μg/m 2/day of rHuIL‐1RI. Physical examinations and laboratory assessments were performed at baseline (day 1), and 8, 15, 22, 29, 43, and 57 days after the start of the study. Analysis of peripheral blood by flow cytometry was performed on days 1 and 29 to determine the effects of rHuIL‐1RI on the distribution and phenotypic characteristics of circulating inflammatory cells. Results. Four of 8 patients who received rHuIL‐1RI at 1,000 μg/m 2/day demonstrated improvement in at least 1 of 8 individual measures of disease activity; however, only 1 of these 4 patients experienced clinically relevant improvement as defined by predetermined criteria. None of the patients treated with smaller doses of rHuIL‐1RI, and none of the placebo‐treated control patients, experienced any improvement as defined by the predetermined criteria. Monocyte cell surface IL‐1α was significantly reduced following treatemnt with rHuIL‐1RI at each dosage. Administration of rHuIL‐1RI was stopped prematurely because of dose‐limiting rashes in 2 pateints treated with 1,000 μg/m 2/day. No other adverse events prevented completion of the study. Conclusion. Only 1 patient, who was treated with the highest concentration of rHuIL‐1RI employed (1,000 μg/m 2/day), demostrated clinically relevant improvement in this phase I study on this small group of patients with active RA. Dose‐limiting toxicity was also observed in 2 pateints treated with this highest concentration of rHuIL‐1RI. Treatment with rHuIL‐1RI did result in a reduction of monocyte cell surface IL‐1α, which indicates that the dosages of rHuIL‐1RI employed were functional.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoregulatory Feedback Between Interleukin-1 and Glucocorticoid Hormones
Besedovsky, H., del Rey, A., Sorkin, E., & Dinarello, C. A. (1986) · Science · doi:10.1126/science.3014662 · Cited by 1,519
Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor
Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P., & Vale, W. (1987) · Science · doi:10.1126/science.2821621 · Cited by 1,504
Cited by
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
Management of Graves’ Ophthalmopathy: Reality and Perspectives*
Bartalena, L., Pinchera, A., & Marcocci, C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0393 · Cited by 677
Anti-Cytokine Therapy for Rheumatoid Arthritis
Maini, R. N., & Taylor, P. C. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.207 · Cited by 376
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Kay, J. (2004) · Rheumatology · doi:10.1093/rheumatology/keh201 · Cited by 280
Pro-and Anti-inflammatory Cytokines in Rheumatoid Arthritis
Isomäki, P., & Punnonen, J. (1997) · Annals of Medicine · doi:10.3109/07853899709007474 · Cited by 260
Metadata
- Authors
- Drevlow, B. E., Lovis, R., Haag, M. A., Sinacore, J. M., Jacobs, C., Blosche, C., Landay, A., Moreland, L. W., & Pope, R. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1996-02
- Volume
- 39
- Issue
- 2
- Pages
- 257-265
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1974603163
- Cited by
- 103
- References
- 2
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.